Ovid Therapeutics (OVID) Operating Margin (2020 - 2026)

Ovid Therapeutics (OVID) has reported Operating Margin for 7 consecutive years, with 2141.61% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Margin fell 206073.0% year-over-year to 2141.61%; the trailing twelve-month figure through Jun 2026 stood at 3686.67% (down 306164.0% YoY), and the FY2025 full-year result was 585.2%, up 1034854.0% from the prior year.
• Operating Margin slipped to 2141.61% in Q2 2026 per OVID's latest filing, from 1712.12% in the prior quarter.
• Across five years, Operating Margin topped out at 80.88% in Q2 2025 and bottomed at 115329.27% in Q3 2022.
• Historically, Operating Margin has averaged 17299.9% across 5 years, with a median of 11402.01% in 2023.
• The widest YoY moves for Operating Margin: up 10429349 bps in 2023, down 2143817 bps in 2023.
• Over 5 years, Operating Margin stood at 26302.75% in 2022, then soared by 51 bps to 12808.45% in 2023, then retreated by 10 bps to 14107.89% in 2024, then soared by 88 bps to 1712.12% in 2025, then retreated by 25 bps to 2141.61% in 2026.
• According to Business Quant data, Operating Margin over the past three periods registered 2141.61%, 1712.12%, and 9487.12% for Q2 2026, Q4 2025, and Q3 2025 respectively.